BCR and diffuse large B-cell lymphoma: Also in ABC-DLBCL, a well-defined cancer entity whose survival relies on chronic activation of the BCR-IKK-NF-κB axis, iNUB inhibited NF-κB activity and selectively killed the tumor cells just like conventional IKKβ inhibitors33.